OPEN TO ENROLLMENT

Clinical Trial of Everolimus in Patients with PTEN Mutations

WHO
- Individuals ages 5-45 with a PTEN Mutation who meet a series of safety inclusion criteria

WHAT
- 6-month randomized controlled trial with everolimus
- Evaluate safety of everolimus and its potential to improve neurocognition

HOW
- Developmental Testing
- Safety Blood Tests
- Eye-tracking
- Electrophysiological Measures

For more information please contact Greg Geisel at 617-919-1476 or gregory.geisel@childrens.harvard.edu

The Developmental Synaptopathies Consortium (U54NS092090) is a part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), NCATS. This consortium is funded through a collaboration between the NCATS, the NINDS and the NIMH.